ARDT

Ardent Health, Inc. 10-Q Summary: Q1 2026

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Ardent Health, Inc. operates 30 acute care hospitals across six states (Texas, Oklahoma, New Mexico, New Jersey, Idaho, and Kansas) utilizing a joint venture model with academic medical centers and not-for-profit systems. The company reported 143,350,031 shares of common stock outstanding as of May 1, 2026.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 7.0% ($104.6 million) year-over-year, driven by a 2.0% increase in adjusted admissions and a 5.5% increase in net patient service revenue per adjusted admission.
• Medicaid Supplemental Payments: Revenue from Medicaid supplemental payment programs rose significantly to $187.8 million (vs. $108.9 million in Q1 2025), primarily due to the delayed renewal of New Mexico's Healthcare Delivery and Access Act in the prior year.
• Expense Trends: Total operating expenses increased 7.3% to $1,527.3 million. Professional fees rose 12.9% due to higher costs for hospital-based providers. Other operating expenses increased 26.3%, driven by higher provider assessments and professional liability losses, partially offset by a $10.9 million gain on an investment in a privately held company.
• Non-Operating Gains: Other non-operating gains decreased to $5.9 million from $21.3 million in Q1 2025. The prior year included a $21.5 million insurance recovery related to a 2023 cybersecurity incident; no such recovery was recorded in Q1 2026.
• Cash Flow: Net cash used in operating activities increased to $60.2 million (from $24.8 million used), primarily due to a $32.6 million negative change in net working capital, driven by timing of insurance premium renewals and Medicaid assessments.

Outlook, Risks, and Management Commentary

• Regulatory Impact (OBBBA): Management highlighted the "One Big Beautiful Bill Act" (OBBBA) passed in July 2025. Provisions include work requirements for Medicaid eligibility, restrictions on provider assessments, and caps on Medicaid managed care payments. These changes are expected to negatively impact financial performance in 2026, partially offset by cost reduction initiatives.
• Debt Refinancing: In September 2025, the company refinanced its Term Loan B Facility, reducing interest rates by 50 basis points and extending the maturity to September 2032.
• Liquidity: As of March 31, 2026, available liquidity was $878.9 million, comprising cash and $269.2 million in available capacity under the ABL Credit Agreement.
• Legal Proceedings:
  • Securities Litigation: A putative class action (Postiwala v. Ardent Health) was filed in January 2026 alleging false statements regarding accounts receivable and insurance reserves. A derivative action (Thompson v. Sotir) was also filed in February 2026.
  • Cybersecurity: Litigation related to the November 2023 ransomware incident was settled in October 2024; the case was closed in August 2025.
• Stock Repurchase: The company has a $50.0 million repurchase program authorized in November 2025. As of March 31, 2026, $46.8 million remained available, with no shares repurchased under the program in Q1 2026.

Investor Verification Checklist

• Verify the sustainability of the $78.9 million increase in Medicaid supplemental payment revenue, given the delayed renewal in New Mexico and potential future regulatory caps under the OBBBA.
• Monitor the status and potential financial impact of the pending securities class action and derivative lawsuits filed in early 2026.
• Assess the impact of the OBBBA on future Medicaid reimbursement rates and eligibility requirements in the company's key operating states.
• Review the company's ability to maintain positive operating cash flows, given the significant cash outflow ($60.2 million) in Q1 2026 driven by working capital timing.
• Confirm compliance with financial covenants under the Ventas Master Lease and Senior Secured Credit Facilities, particularly the net leverage and fixed charge coverage ratios.